Kashiv Biosciences, LLC (“Kashiv” or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (“FDA”) has approved its Biologics License Application (“BLA”) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta®. The product will be marketed under the proprietary name FYLNETRA®.
An impact investor can be an individual or investment fund that has co-equal primary goals: to make money and foment positive social change that can last. In some ways, impact investors are “social VCs”—they fund projects and companies that can create positive, measurable impact for the greater good of humanity. Unlike traditional VC investment strategies that tend to take a high risk, high reward approach, impact investing generally focuses on lower risk, more modest or conservative financial investments that yield the most possible good for people and communities.
Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.
BioFactura, a leading developer and manufacturer of biosimilars and biodefense products, is one of the crown jewels of Frederick, Maryland’s growing biotech hub. The company is thriving and has secured strong funding from both private and government sources that see the potential of the company’s StableFast™ biosimilars platform. In May 2021, BioFactura reached an important milestone, announcing that it had moved its first biosimilar product into the clinic.
Over the next few years, thousands of new positions in the biopharma and life sciences industry are expected to open up across the BioHealth Capital Region and the greater Philadelphia area known as Cellicon Valley.
Whether you are fresh out of the university or a seasoned veteran, many job seekers question whether or not they should aim for large biopharmaceutical companies, such as AstraZeneca, Pfizer or GlaxoSmithKline, or look at nimble, growth-stage companies, such as American Gene Technologies, Vita Therapeutics, or BioFactura, Inc., which is currently scaling their cGMP and Quality operations.
Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.
BioFactura Inc. (“BioFactura”), a leading developer of high-value biosimilar and biodefense drugs using its patented StableFast™ platform, announces an agreement with Rani Therapeutics (“Rani”) to assess its Ustekinumab Biosimilar (BFI-751) in combination with Rani’s RaniPill™ platform.
BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event
BioFactura CEO Dr. Darryl Sampey Shares his Entrepreneurial Journey at Frederick’s StartupGrind Event February 26, 2019 Dr. Darryl Sampey has been through the grind as CEO of Frederick’s BioFactura, a [….]
BioFactura Raising Series B Investment to Advance Lead Biosimilar into Phase One Dr. Jeffrey Hausfeld, BioFactura’s Chairman of the Board and Chief Medical Officer has been tasked with raising a Series [….]
Frederick Based Biosimilars Company begins GMP Manufacturing and Scales Headcount Image Credit: prweb.com/releases/2015/12/prweb13140953.htm BioFactura Inc. is a growing biotech company in Frederick, Maryland operating in an exciting and growing field. [….]